|
1
|
Abbas A, Lichtman A and Pillai S: Cellular
and Molecular Immunology. 6th edition. Saunders Elsevier;
Philadelphia, PA: 2007
|
|
2
|
Aly HA: Cancer therapy and vaccination. J
Immunol Methods. 382:1–23. 2012. View Article : Google Scholar
|
|
3
|
Hislop AD, Taylor GS, Sauce D and
Rickinson AB: Cellular responses to viral infection in humans:
lessons from Epstein-Barr virus. Annu Rev Immunol. 25:587–617.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finn OJ: Cancer immunology. N Engl J Med.
358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schreiber TH, Raez L, Rosenblatt JD and
Podack ER: Tumor immunogenicity and responsiveness to cancer
vaccine therapy: the state of the art. Semin Immunol. 22:105–112.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bijker MS, Melief CJ, Offringa R and van
der Burg SH: Design and development of synthetic peptide vaccines:
past, present and future. Expert Rev Vaccines. 6:591–603. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bode C, Zhao G, Steinhagen F, Kinjo T and
Klinman DM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines.
10:499–511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klinman DM, Currie D, Gursel I and
Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants.
Immunol Rev. 199:201–216. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krieg AM: CpG motifs in bacterial DNA and
their immune effects. Annu Rev Immunol. 20:709–760. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu RS, Targoni OS, Krieg AM, Lehmann PV
and Harding CV: CpG oligodeoxynucleotides act as adjuvants that
switch on T helper 1 (Th1) immunity. J Exp Med. 186:1623–1631.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carson DA and Raz E: Oligonucleotide
adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med.
186:1621–1622. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis HL, Weeratna R, Waldschmidt TJ,
Tygrett L, Schorr J and Krieg AM: CpG-DNA is a potent enhancer of
specific immunity in mice immunized with recombinant hepatitis B
surface antigen. J Immunol. 160:870–876. 1998.PubMed/NCBI
|
|
13
|
Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, et
al: Immunostimulation and anti-DNA antibody production by backbone
modified CpG-DNA. Biochem Biophys Res Commun. 379:362–367. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lipford GB, Sparwasser T, Zimmermann S,
Heeg K and Wagner H: CpG-DNA-mediated transient lymphadenopathy is
associated with a state of Th1 predisposition to antigen-driven
responses. J Immunol. 165:1228–1235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heikenwalder M, Polymenidou M, Junt T,
Sigurdson C, Wagner H, et al: Lymphoid follicle destruction and
immunosuppression after repeated CpG oligodeoxynucleotide
administration. Nat Med. 10:187–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng GM, Nilsson IM, Verdrengh M, Collins
LV and Tarkowski A: Intra-articularly localized bacterial DNA
containing CpG motifs induces arthritis. Nat Med. 5:702–705. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee KW, Jung J, Lee Y, Kim TY, Choi SY, et
al: Immunostimulatory oligodeoxynucleotide isolated from genome
wide screening of Mycobacterium bovis chromosomal DNA. Mol
Immunol. 43:2107–2118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Henriksen-Lacey M, Korsholm KS, Andersen
P, Perrie Y and Christensen D: Liposomal vaccine delivery systems.
Expert Opin Drug Deliv. 8:505–519. 2011. View Article : Google Scholar
|
|
19
|
Suzuki Y, Wakita D, Chamoto K, Narita Y,
Tsuji T, et al: Liposome-encapsulated CpG oligodeoxynucleotides as
a potent adjuvant for inducing type 1 innate immunity. Cancer Res.
64:8754–8760. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, et
al: Production of antibodies with peptide-CpG-DNA-liposome complex
without carriers. BMC Immunol. 12:292011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim D, Kwon S, Ahn CS, Lee Y, Choi SY,
Park J, Kwon HY and Kwon HJ: Adjuvant effect of
liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep.
44:758–763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim D, Kwon HJ and Lee Y: Activation of
Toll-like receptor 9 and production of epitope specific antibody by
liposome-encapsulated CpG-DNA. BMB Rep. 44:607–612. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, et
al: Tetraspanin TM4SF5 mediates loss of contact inhibition through
epithelial-mesenchymal transition in human hepatocarcinoma. J Clin
Invest. 118:1354–1366. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim
YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y and Kwon HJ:
Prevention and therapy of hepatocellular carcinoma by vaccination
with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS
One. 7:e331212012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshiji H, Kuriyama S, Ways DK, Yoshii J
and Miyamoto Y: Protein kinase C lies on the signaling pathway for
vascular endothelial growth factor-mediated tumor development and
angiogenesis. Cancer Res. 59:4413–4418. 1999.PubMed/NCBI
|
|
26
|
Yoshiji H, Kuriyama S, Kawata M, Yoshii J,
Ikenaka Y, et al: The angiotensin-I-converting enzyme inhibitor
perindopril suppresses tumor growth and angiogenesis: possible role
of the vascular endothelial growth factor. Clin Cancer Res.
7:1073–1078. 2001.
|
|
27
|
Richard K, Pierce SK and Song W: The
agonists of TLR4 and 9 are sufficient to activate memory B cells to
differentiate into plasma cells in vitro but not in vivo. J
Immunol. 181:1746–1752. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McHeyzer-Williams LJ and McHeyzer-Williams
MG: Antigen-specific memory B cell development. Annu Rev Immunol.
23:487–513. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayakawa K, Ishii R, Yamasaki K, Kishimoto
T and Hardy RR: Isolation of high-affinity memory B cells:
phycoerythrin as a probe for antigen-binding cells. Proc Natl Acad
Sci USA. 84:1379–1383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ben-Yedidia T and Arnon R: Epitope-based
vaccine against influenza. Expert Rev Vaccines. 6:939–948. 2007.
View Article : Google Scholar
|
|
31
|
Ben-Yedidia T and Arnon R: Design of
peptide and polypeptide vaccines. Curr Opin Biotechnol. 8:442–448.
1997. View Article : Google Scholar
|
|
32
|
Müller-Pillasch F, Wallrapp C, Lacher U,
Friess H, Büchler M, Adler G and Gress TM: Identification of a new
tumour-associated antigen TM4SF5 and its expression in human
cancer. Gene. 208:25–30. 1998.PubMed/NCBI
|
|
33
|
Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, et
al: Blockade of four-transmembrane L6 family member 5
(TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic
chalcone derivative. Hepatology. 49:1316–1325. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lekishvili T, Fromm E, Mujoomdar M and
Berditchevski F: The tumour-associated antigen L6 (L6-Ag) is
recruited to the tetraspanin-enriched microdomains: implication for
tumor cell motility. J Cell Sci. 121:685–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Plotkin SA: Vaccines: correlates of
vaccine-induced immunity. Clin Infect Dis. 47:401–409. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galli G, Medini D, Borgogni E, Zedda L,
Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert
AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G and Castellino
F: Adjuvanted H5N1 vaccine induces early CD4+ T cell
response that predicts long-term persistence of protective antibody
levels. Proc Natl Acad Sci USA. 106:3877–3882. 2009.PubMed/NCBI
|
|
37
|
Vieira P and Rajewsky K: Persistence of
memory B cells in mice deprived of T cell help. Int Immunol.
2:487–494. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cancro MP: The persistence of memory: a
unique niche for IgG memory B cells. Proc Natl Acad Sci USA.
107:12737–12738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bernasconi NL, Onai N and Lanzavecchia A:
A role for Toll-like receptors in acquired immunity: up-regulation
of TLR9 by BCR triggering in naive B cells and constitutive
expression in memory B cells. Blood. 101:4500–4504. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chiriva-Internati M, Yu Y, Mirandola L,
Jenkins MR, Chapman C, Cannon M, Cobos E and Kast WM: Cancer testis
antigen vaccination affords long-term protection in a murine model
of ovarian cancer. PLoS One. 5:e104712010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cerkovnik P, Novakovic BJ, Stegel V and
Novakovic S: Tumor vaccine composed of C-class CpG
oligodeoxynucleotides and irradiated tumor cells induces long-term
antitumor immunity. BMC Immunol. 11:452010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chikh G and Schutze-Redelmeier MP:
Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep.
22:339–353. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang JS, Choi MJ, Cheong HS and Kim K:
Development of Th1-mediated CD8+ effector T cells by
vaccination with epitope peptides encapsulated in pH-sensitive
liposomes. Vaccine. 19:3608–3614. 2001.PubMed/NCBI
|
|
44
|
Gursel I, Gursel M, Ishii KJ and Klinman
DM: Sterically stabilized cationic liposomes improve the uptake and
immunostimulatory activity of CpG oligonucleotides. J Immunol.
167:3324–3328. 2001. View Article : Google Scholar : PubMed/NCBI
|
